Revlimid (Lenalidomide) Patent Expiration, LOE Window & CMS Spending
Revlimid (Lenalidomide) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2027-04-27 (last listed 2028-03-08), 19 AB generics, $4.43B 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bristol Myers Squibb |
| FDA Application & Pathway | N021880 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2027-04-27 |
| Last Listed Patent or Exclusivity Date | 2028-03-08 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 19 |
| 2024 CMS Total Public Spend | $4.43B |
| 2024 Medicare Part D Spend | $4.18B |
| 2024 Medicaid Spend | $254.4M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.